I recently wrote about the popular diabetes and PCOS drug metformin, and its potentially fatal side effects involving vitamin deficiencies and metabolic acidosis. Now, it appears, that metformin, along with several other highly prescribed diabetes medications, have been linked to heart failure, cancer, and hypoglycemia.
Studies revealed that prescription meds containing saxagliptin and alogliptin increase the risk of heart failure in patients with a history of cardiovascular or kidney disease or those with multiple risk factors for vascular disease(1). Saxagliptin was also shown to incite hypoglycemia(2).
Another diabetes drug making headlines (and not in a good way) is pioglitazone. According to a cohort study following more than 145,000 participants, the use of pioglitazone increased the risk of developing bladder cancer by up to 63%(3).
Saxagliptin and alogliptin are drugs known as dipeptidyl peptidase-4 inhibitors (DDP-4) and can be found in the following diabetes medications:
- Kombiglyze XR
The FDA has acknowledged these dangerous side effects and they’re urging patients to discuss the situation with their doctor before eliminating the prescriptions.
Most People Have Cardiovascular Disease
It’s important to note that, although researchers indicate that only those with previous “risk factors” are in jeopardy, a large portion of the population may be completely unaware that they are in danger. As cardiologists point out, often times the first sign of cardiovascular disease is a sudden and fatal heart attack or stroke. This is because many people mistake the absence of diagnosed disease for the existence of health.
History tells us that nearly all people have some level cardiovascular disease, beginning as early as childhood(4,5). A perfect example of the early onset of cardiovascular disease can be found in a 1953 study in the Journal of the American Medical Association, detailing the findings of autopsies performed on soldiers killed in action or by accidental death the Korean War(6). Of the 300 men examined, 77.3% showed “gross evidence of arteriosclerosis”- that is, a hardening of the arteries due to a build of plaque and damage to the arterial walls. Some of the soldiers exhibited extreme cardiovascular disease, with 90% or more of their arteries blocked off. The most surprising part of this study is the fact that the average age of 200 of the examined soldiers was 22.1 years of age! Researchers noted that that ages of the first 98 soldiers examined, were not recorded. However, they did state that the oldest patient in this group was only 33.
Prevent And Reverse Disease Without Medication
So what can you do to avoid cardiovascular disease as a result of using your prescribed diabetes medication?
Of course, the best thing you can do is minimize your risk for a heart attack or stroke.
At particular risk is anyone who eats animal products, as this type of food is known to contribute to and cause cardiovascular disease. This is due to the fact that when animal proteins are consumed, they cause your liver to secrete substances known as trimethylamine N-oxide (TMAO) and gamma butyrobetaine (yBB). Both TMAO and yBB promote and accelerate the formation of plaque in the arteries, and TMAO in particular, reduces your body’s natural ability to excrete plaque.
To learn how to prevent and reverse diabetes, heart disease, and even cancer, naturally, and all at the same time, I highly recommend that you read the following books:
The China Study: The Most Comprehensive Study of Nutrition Ever Conducted And the Startling Implications for Diet, Weight Loss, and Long-Term Health, by T Colin Campbell, Ph.D. and Thomas M. Campbell II, M.D.
- “FDA: 2 Diabetes Drugs May Be Linked to Heart Failure Risk: MedlinePlus.” U.S National Library of Medicine. April 5, 2016. https://www.nlm.nih.gov/medlineplus/news/fullstory_158144.html.
- Scirica, Benjamin M., Deepak L. Bhatt, Eugene Braunwald, P. Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D. Wiviott, Elaine B. Hoffman, Matthew A. Cavender, Jacob A. Udell, Nihar R. Desai, Ofri Mosenzon, Darren K. Mcguire, Kausik K. Ray, Lawrence A. Leiter, and Itamar Raz. “Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus.” New England Journal of Medicine N Engl J Med 369, no. 14 (October 03, 2013): 1317-326. doi:10.1056/nejmoa1307684.
- Tuccori, Marco, Kristian B. Filion, Hui Yin, Oriana H. Yu, Robert W. Platt, and Laurent Azoulay. “Pioglitazone Use and Risk of Bladder Cancer: Population Based Cohort Study.” Bmj, March 30, 2016, I1541. doi:10.1136/bmj.i1541.
- Voller, Robert D., and William B. Strong. “Pediatric Aspects of Atherosclerosis.” American Heart Journal 101, no. 6 (June 1981): 815-36. doi:10.1016/0002-8703(81)90621-9.
- Armstrong, N., J. Balding, P. Gentle, and B. Kirby. “Estimation of Coronary Risk Factors in British Schoolchildren: A Preliminary Report.” British Journal of Sports Medicine 24, no. 1 (March 24, 1990): 61-66. doi:10.1136/bjsm.24.1.61.
- Enos, William F. “Coronary Disease Among United States Soldiers Killed In Action In Korea.” JAMA Journal of the American Medical Association 152, no. 12 (July 18, 1953): 1090. doi:10.1001/jama.1953.03690120006002.